

Special Issue

From Mutation and Repair to Therapeutics

Message from the Guest Editors

DNA research has grown from the structural aspects of non-canonical base pairing to pseudoknots and other unorthodox arrangements, from the infrequent misreplication of unaltered bases to DNA lesion-derived mutagenesis, and from biomarkers to therapeutics. This Special Issue of *DNA* will explore recent advances in some of these areas, with an emphasis on the DNA damage-induced alteration of cellular functions and DNA therapeutics. In this issue, the primary focus will be on recent advances made in the following topics.

- DNA adducts and lesions: formation, repair, translesion synthesis, and mutational signatures;
- DNA modifications in genetics and epigenetics;
- Nucleic acid modifications as biomarkers in chemistry, biology, and diseases;
- DNA/RNA therapeutics.

The type of papers that will be considered for publication in this issue are research articles, communications, reviews, and perspectives.

Guest Editors

Prof. Dr. Ashis Basu

Department of Chemistry, University of Connecticut, Storrs, CT 06269, USA

Dr. Deyu Li

Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA

Deadline for manuscript submissions

closed (30 September 2022)



DNA

an Open Access Journal
by MDPI

Tracked for Impact Factor



mdpi.com/si/107463

DNA

Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
dna@mdpi.com

mdpi.com/journal/

[dna](https://mdpi.com/journal/dna)





DNA

an Open Access Journal
by MDPI

Tracked for Impact Factor



[mdpi.com/journal/
dna](https://mdpi.com/journal/dna)



About the Journal

Message from the Editor-in-Chief

Since the first human and mouse genome sequence assemblies over 20 years ago, hundreds of species are now complete, impacting on diagnostics, medicine, agriculture and the environment. Taking a “sequence to consequence” and “structure to nature” philosophy with clearly written, accessible manuscripts, *DNA* will publish novel research findings, reviews and communications in DNA-related technologies, genome structures, DNA-targeted therapies, bioinformatics and cytogenomics. As pioneers in DNA technology, we owe it to the next generation to take the lead in carving a new path that the enigmatic double helix at the core of our essence shows us. We look forward to hearing from you and distributing your insights to the community.

Editor-in-Chief

Prof. Dr. Yves Pommier

Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology Center for Cancer Research, NCI, National Institutes of Health, Bethesda, MD 20892, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science) and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 36 days after submission; acceptance to publication is undertaken in 14.7 days (median values for papers published in this journal in the second half of 2025).